The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
Open accessAbstract
Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to antibody production we serially monitored 24-hour proteinuria and antibody titer in patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m(2)) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0-145.4) months, 84 of 132 rituximab-treated patients achieved complete or partial NS remission (primary end point), and 25 relapsed after remission. Outcomes of patients with or without detectable anti-PLA2R antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti-PLA2R antibody titer at baseline (P=0.001) and full antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P<0.001) strongly predicted remission. All 25 complete remissions were preceded by complete anti-PLA2R antibody depletion. On average, 50% anti-PLA2R titer reduction preceded equivalent proteinuria reduction by 10 months. Re-emergence of circulating antibodies predicted disease relapse (HR, 6.54; 95% CI, 1.57 to 27.40; P=0.01), whereas initial complete remission protected from the event (HR, 6.63; 95% CI, 2.37 to 18.53; P<0.001). Eighteen patients achieved persistent antibody depletion and complete remission and never relapsed. Outcome was independent of PLA2R1 and HLA-DQA1 polymorphisms and of previous immunosuppressive treatment. Therefore, assessing circulating anti-PLA2R autoantibodies and proteinuria may help in monitoring disease activity and guiding personalized rituximab therapy in nephrotic patients with primary MN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
Beck, L. H., Bonegio, R. G. B., Lambeau, G., Beck, D. M., Powell, D. W., Cummins, T. D., Klein, J. B., & Salant, D. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810457 · Cited by 2,347
Royston, P. J., & Sauerbrei, W. (2008) · Cited by 601
Antenatal Membranous Glomerulonephritis Due to Anti–Neutral Endopeptidase Antibodies
Debiec, H., Guigonis, V., Mougenot, B., Decobert, F., Haymann, J.-P., Bensman, A., Deschênes, G., & Ronco, P. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012895 · Cited by 528
Self-citationRisk HLA-DQA1 and PLA 2 R1 Alleles in Idiopathic Membranous Nephropathy
Stanescu, H. C., Arcos-Burgos, M., Medlar, A., Bockenhauer, D., Kottgen, A., Dragomirescu, L., Voinescu, C., Patel, N., Pearce, K., Hubank, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009742 · Cited by 523
Self-citationRituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
Beck, L. H., Fervenza, F. C., Beck, D. M., Bonegio, R. G. B., Malik, F. A., Erickson, S. B., Cosio, F. G., Cattran, D. C., & Salant, D. J. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111125 · Cited by 471
Hoxha, E., Thiele, I., Zahner, G., Panzer, U., Harendza, S., & Stahl, R. A. K. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040430 · Cited by 353
Kanigicherla, D., Gummadova, J., McKenzie, E. A., Roberts, S. A., Harris, S., Nikam, M., Poulton, K., McWilliam, L., Short, C. D., Venning, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.486 · Cited by 347
Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy
Hofstra, J. M., Debiec, H., Short, C. D., Pellé, T., Kleta, R., Mathieson, P. W., Ronco, P., Brenchley, P. E., & Wetzels, J. F. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030242 · Cited by 321
Self-citationRituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080610 · Cited by 299
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome
Ruggenenti, P., Ruggiero, B., Cravedi, P., Vivarelli, M., Massella, L., Marasà, M., Chianca, A., Rubis, N., Ene-Iordache, B., Rudnicki, M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030251 · Cited by 267
Self-citation
Cited by
Primary Membranous Nephropathy
Couser, W. G. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11761116 · Cited by 690
Vivarelli, M., Massella, L., Ruggiero, B., & Emma, F. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05000516 · Cited by 557
Self-citationRituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Dahan, K., Debiec, H., Plaisier, E., Cachanado, M., Rousseau, A., Wakselman, L., Michel, P.-A., Mihout, F., Dussol, B., Matignon, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040449 · Cited by 439
Self-citationA Proposal for a Serology-Based Approach to Membranous Nephropathy
De Vriese, A. S., Glassock, R. J., Nath, K. A., Sethi, S., & Fervenza, F. C. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016070776 · Cited by 372
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care
Ronco, P., & Debiec, H. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60731-0 · Cited by 369
Self-citation
Metadata
- Authors
- Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., Suardi, F., Gagliardini, E., Orisio, S., Benigni, A., Ronco, P., & Remuzzi, G.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2015-10
- Volume
- 26
- Issue
- 10
- Pages
- 2545-2558
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2127127482
- Cited by
- 376
- References
- 19
- FWCI
- 24.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. https://app.cochat.ai/papers/10.1681/asn.2014070640
- The paper
- Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., Suardi, F., Gagliardini, E., Orisio, S., Benigni, A., Ronco, P., & Remuzzi, G. (2015). Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2014070640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.